Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

BACKGROUND: The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respir Res
Autors principals: Liu, Mark C., Chipps, Bradley, Munoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Smith, Steven G., Price, Robert G., Galkin, Dmitry V., Azmi, Jay, Mouneimne, Dalal, Albers, Frank C., Chapman, Kenneth R.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111733/
https://ncbi.nlm.nih.gov/pubmed/33971856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01733-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars